Synthesis of Enantiostructured Triacylglycerol Prodrugs Constituting an Active Drug Located at Terminal -1 and -3 Positions of the Glycerol Backbone

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2025 Mar 13

PMID 40076218

Authors

Lena Ros Jonsdottir

Gudmundur G Haraldsson

Affiliations

Soon will be listed here.

Abstract

The current paper reports the asymmetric synthesis of a focused library of enantiostructured triacylglycerols (TAGs) constituting a potent drug of the NSAID type (ibuprofen or naproxen) along with a pure bioactive n-3 polyunsaturated fatty acid (PUFA) intended as a novel type of prodrug. In this second category, a TAG prodrug of the terminal -1 or -3 position of the glycerol skeleton is acylated with a single saturated medium-chain fatty acid (C6, C8, C10, or C12), and another with the drug entity; the PUFA (EPA or DHA) is located in the -2 position. This was accomplished by a six-step chemoenzymatic approach, two of which were promoted by a lipase, starting from enantiopure ()- and ()-solketals. The highly regioselective immobilized lipase (CAL-B) played a crucial role in the regiocontrol of the synthesis. The most challenging key step involved the incorporation of the drugs that were activated as oxime esters by the lipase exclusively in the terminal position of glycerol that is protected as a benzyl ether. All combinations, a total of 32 such prodrug TAGs, were prepared, isolated, and fully characterized, along with 24 acylglycerol intermediates, obtained in very-high-to-excellent yields in the majority of cases.

References

Serhan C . Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014; 510(7503):92-101. PMC: 4263681. DOI: 10.1038/nature13479. View

Lopes P, Alfaia C, Pestana J, Prates J . Structured Lipids Engineering for Health: Novel Formulations Enriched in -3 Long-Chain Polyunsaturated Fatty Acids with Potential Nutritional Benefits. Metabolites. 2023; 13(10). PMC: 10608893. DOI: 10.3390/metabo13101060. View

Serhan C, Petasis N . Resolvins and protectins in inflammation resolution. Chem Rev. 2011; 111(10):5922-43. PMC: 3192290. DOI: 10.1021/cr100396c. View

Magnusson C, Haraldsson G . Activation of n-3 polyunsaturated fatty acids as oxime esters: a novel approach for their exclusive incorporation into the primary alcoholic positions of the glycerol moiety by lipase. Chem Phys Lipids. 2012; 165(7):712-20. DOI: 10.1016/j.chemphyslip.2012.07.005. View

Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T . Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008; 7(3):255-70. DOI: 10.1038/nrd2468. View

Innes J, Calder P . Marine Omega-3 (N-3) Fatty Acids for Cardiovascular Health: An Update for 2020. Int J Mol Sci. 2020; 21(4). PMC: 7072971. DOI: 10.3390/ijms21041362. View

Serhan C, Yang R, Martinod K, Kasuga K, Pillai P, Porter T . Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med. 2008; 206(1):15-23. PMC: 2626672. DOI: 10.1084/jem.20081880. View

Chan D, Nguyen M, Watts G, Ooi E, Barrett P . Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. Am J Clin Nutr. 2010; 91(4):900-6. DOI: 10.3945/ajcn.2009.28422. View

Zaro J . Lipid-based drug carriers for prodrugs to enhance drug delivery. AAPS J. 2014; 17(1):83-92. PMC: 4287280. DOI: 10.1208/s12248-014-9670-z. View

10.

Bays H, Braeckman R, Ballantyne C, Kastelein J, Otvos J, Stirtan W . Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2013; 6(6):565-72. DOI: 10.1016/j.jacl.2012.07.001. View

11.

Kodali D, Tercyak A, Fahey D, Small D . Acyl migration in 1,2-dipalmitoyl-sn-glycerol. Chem Phys Lipids. 1990; 52(3-4):163-70. DOI: 10.1016/0009-3084(90)90111-4. View

12.

Jonsdottir L, Haraldsson G . Synthesis of Enantiostructured Triacylglycerols Possessing a Saturated Fatty Acid, a Polyunsaturated Fatty Acid and an Active Drug Intended as Novel Prodrugs. Molecules. 2024; 29(23). PMC: 11643827. DOI: 10.3390/molecules29235745. View

13.

Hoy S, Keating G . Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia. Drugs. 2009; 69(8):1077-105. DOI: 10.2165/00003495-200969080-00008. View

14.

Tatsuno I, Saito Y, Kudou K, Ootake J . Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study. J Clin Lipidol. 2013; 7(3):199-207. DOI: 10.1016/j.jacl.2013.01.006. View

15.

Kalpio M, Magnusson J, Gudmundsson H, Linderborg K, Kallio H, Haraldsson G . Synthesis and enantiospecific analysis of enantiostructured triacylglycerols containing n-3 polyunsaturated fatty acids. Chem Phys Lipids. 2020; 231:104937. DOI: 10.1016/j.chemphyslip.2020.104937. View

16.

Haraldsdottir H, Gudmundsson H, Linderborg K, Yang B, Haraldsson G . Chemoenzymatic Synthesis of ABC-Type Enantiostructured Triacylglycerols by the Use of the -Methoxybenzyl Protective Group. Molecules. 2024; 29(7). PMC: 11013301. DOI: 10.3390/molecules29071633. View

17.

Lambert D . Rationale and applications of lipids as prodrug carriers. Eur J Pharm Sci. 2000; 11 Suppl 2:S15-27. DOI: 10.1016/s0928-0987(00)00161-5. View

18.

Jacobson T, Glickstein S, Rowe J, Soni P . Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012; 6(1):5-18. DOI: 10.1016/j.jacl.2011.10.018. View

19.

Rautio J, Meanwell N, Di L, Hageman M . The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discov. 2018; 17(8):559-587. DOI: 10.1038/nrd.2018.46. View

20.

Tatsuno I, Saito Y, Kudou K, Ootake J . Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study. J Clin Lipidol. 2013; 7(6):615-25. DOI: 10.1016/j.jacl.2013.09.002. View